Jie Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jie Bai has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Sujun Zheng
First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China
2 shared publications Hui Liu
1 shared publication- Jingya Dong
Program in Integrated Biology and Medicine Duke–NUS Medical School, Singapore Singapore 169857 Singapore
1 shared publication - Lei Luo
Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing You An Hospital, Capital Medical University, Beijing, China
1 shared publication Li Bai
1 shared publication- Li Bai
Chinese PLA General Hospital
1 shared publication
Latest Publications
- Open Access
- 25 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , 1-24
Single‐Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion
Neutrophils play a critical role in the pathogenesis of autoimmune diseases, including myasthenia gravis (MG), but their specific function in MG exacerbations remains unclear. This study utilizes single‐cell RNA sequencing (scRNA‐seq) of bone marrow and peripheral blood from MG patients during acute exacerbations, combined with experimental autoimmune myasthenia gravis (EAMG) mouse models and clinical cohort analyses, to investigate the potential involvement of a neutrophil–B‐cell activating factor (BAFF) –plasma cell axis. The results reveal that, during MG acute exacerbation, bone‐marrow neutrophils exhibit significantly enhanced maturation. Upon migration to the peripheral blood, these neutrophils secrete increased amounts of BAFF, further promoting pathological B‐cell differentiation and plasma cell activation. Moreover, gene knockout models and serum cytokine analyses reveal that the IFN‐γ signaling pathway is a key driver of this excessive BAFF secretion, supporting the existence of a neutrophil–BAFF–plasma cell interaction relevant to MG exacerbation. Clinical data analysis shows that MG patients with high baseline neutrophil levels derive greater benefit from treatment with the BAFF/APRIL dual‐target inhibitor telitacicept. Collectively, this study reveals the mechanistic link between neutrophil activation and MG exacerbation, providing insights that may inform precision‐targeted immunotherapy.
- 25 September 2025
- Published by Wiley in Advanced Science
- Vol. 12 (45) , 1-24
Open AccessSingle‐Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion
Neutrophils play a critical role in the pathogenesis of autoimmune diseases, including myasthenia gravis (MG), but their specific function in MG exacerbations remains unclear. This study utilizes single‐cell RNA sequencing (scRNA‐seq) of bone marrow and peripheral blood from MG patients during acute exacerbations, combined with experimental autoimmune myasthenia gravis (EAMG) mouse models and clinical cohort analyses, to investigate the potential involvement of a neutrophil–B‐cell activating factor (BAFF) –plasma cell axis. The results reveal that, during MG acute exacerbation, bone‐marrow neutrophils exhibit significantly enhanced maturation. Upon migration to the peripheral blood, these neutrophils secrete increased amounts of BAFF, further promoting pathological B‐cell differentiation and plasma cell activation. Moreover, gene knockout models and serum cytokine analyses reveal that the IFN‐γ signaling pathway is a key driver of this excessive BAFF secretion, supporting the existence of a neutrophil–BAFF–plasma cell interaction relevant to MG exacerbation. Clinical data analysis shows that MG patients with high baseline neutrophil levels derive greater benefit from treatment with the BAFF/APRIL dual‐target inhibitor telitacicept. Collectively, this study reveals the mechanistic link between neutrophil activation and MG exacerbation, providing insights that may inform precision‐targeted immunotherapy.
- Open Access
- 11 March 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults
Bilirubin encephalopathy/kernicterus is very rare in adults. This study is aimed to investigate the clinical manifestations and genetic features of two patients with UGT1A1-related kernicterus.
- 11 March 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessUGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults
Bilirubin encephalopathy/kernicterus is very rare in adults. This study is aimed to investigate the clinical manifestations and genetic features of two patients with UGT1A1-related kernicterus.
- Open Access
- 31 October 2019
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 1073
Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia
The potential for genetic variation to cause adult unconjugated hyperbilirubinemia is increasingly being recognized. However, the cumulative effects of genetic variants have not been fully illuminated. The current study aimed to investigate the effects of uridine diphospho-glucuronosyl transferase 1A1 (UGT1A1) and/or solute carrier organic anion transporter family member 1B (SLCO1B) polymorphic variants and their combined effects on mild unconjugated hyperbilirubinemia in Chinese adults. Fourteen genetic variants in the UGT1A1 or SLCO1B gene were genotyped through sequencing in 148 adults with unconjugated hyperbilirubinemia and 158 healthy controls. Variants c.-3275T > G, (TA)6>(TA)7, c.211G > A or c.1091C > T within the UGT1A1 gene as well as c.521T > C within the SLCO1B1 gene appear to be genetic risk factors for inherited unconjugated hyperbilirubinemia. After adjusting for covariates, the results of multivariate logistic regressions revealed that odds ratios (ORs) [(with 95% confidence interval (CI)] of these five variants were 2.35 (95% CI: 1.37–4.01, p = 0.002), 2.38 (95% CI: 1.35–4.20, p = 0.003), 2.99 (95% CI: 1.71–5.21, p < 0.001), 7.60 (95% CI: 1.99–28.96, p = 0.003), and 2.54 (95% CI: 1.27–5.11, p = 0.009), respectively. The OR for unconjugated hyperbilirubinemia is positively correlated with the cumulative number of these five variants in adults. And the greater the number of genetic variations, the higher the total bilirubin level. Adults carrying diplotype 3/4 (homozygous c.-3275T > G and heterozygous (TA)6>(TA)7) had higher bilirubin levels than those with diplotypes 1/3 (heterozygous c.-3275T > G and (TA)6>(TA)7)) or 1/4 (heterozygous c.-3275T > G) (P < 0.05). Similarly, bilirubin levels in individuals with diplotype 2/4 (heterozygous c.-3275T > G and c.211G > A) were higher than adults carrying diplotypes 1/2 (heterozygous c.211G > A) or 1/4 (P < 0.001). For subjects with heterozygous or homozygous variant c.211G> A, as the number of c.521T > C alleles variation increased, the incidence of unconjugated hyperbilirubinemia increased, but it was not statistically significant. Our results indicate that variants of UGT1A1 and/or SLCO1B1 have combined effects on Chinese adult mild unconjugated hyperbilirubinemia.
- 31 October 2019
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 10, 1073
Open AccessCombined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia
The potential for genetic variation to cause adult unconjugated hyperbilirubinemia is increasingly being recognized. However, the cumulative effects of genetic variants have not been fully illuminated. The current study aimed to investigate the effects of uridine diphospho-glucuronosyl transferase 1A1 (UGT1A1) and/or solute carrier organic anion transporter family member 1B (SLCO1B) polymorphic variants and their combined effects on mild unconjugated hyperbilirubinemia in Chinese adults. Fourteen genetic variants in the UGT1A1 or SLCO1B gene were genotyped through sequencing in 148 adults with unconjugated hyperbilirubinemia and 158 healthy controls. Variants c.-3275T > G, (TA)6>(TA)7, c.211G > A or c.1091C > T within the UGT1A1 gene as well as c.521T > C within the SLCO1B1 gene appear to be genetic risk factors for inherited unconjugated hyperbilirubinemia. After adjusting for covariates, the results of multivariate logistic regressions revealed that odds ratios (ORs) [(with 95% confidence interval (CI)] of these five variants were 2.35 (95% CI: 1.37–4.01, p = 0.002), 2.38 (95% CI: 1.35–4.20, p = 0.003), 2.99 (95% CI: 1.71–5.21, p < 0.001), 7.60 (95% CI: 1.99–28.96, p = 0.003), and 2.54 (95% CI: 1.27–5.11, p = 0.009), respectively. The OR for unconjugated hyperbilirubinemia is positively correlated with the cumulative number of these five variants in adults. And the greater the number of genetic variations, the higher the total bilirubin level. Adults carrying diplotype 3/4 (homozygous c.-3275T > G and heterozygous (TA)6>(TA)7) had higher bilirubin levels than those with diplotypes 1/3 (heterozygous c.-3275T > G and (TA)6>(TA)7)) or 1/4 (heterozygous c.-3275T > G) (P < 0.05). Similarly, bilirubin levels in individuals with diplotype 2/4 (heterozygous c.-3275T > G and c.211G > A) were higher than adults carrying diplotypes 1/2 (heterozygous c.211G > A) or 1/4 (P < 0.001). For subjects with heterozygous or homozygous variant c.211G> A, as the number of c.521T > C alleles variation increased, the incidence of unconjugated hyperbilirubinemia increased, but it was not statistically significant. Our results indicate that variants of UGT1A1 and/or SLCO1B1 have combined effects on Chinese adult mild unconjugated hyperbilirubinemia.